Company Overview and News

 
Fears of secrecy as Qld Government set to ban information requests on mining rehabilitation fund

2018-09-13 abc.net.au
A new mining and gas rehabilitation fund to contain hundreds of millions of dollars in contributions from resources companies will be shrouded in secrecy, with the Queensland Government granting a blanket exclusion from right to information requests after industry concerns.
XQL

 
How south-east Queensland measures up to the world

2018-08-07 smh.com.au
South-east Queensland ranks last in export businesses, last in international internet connectivity, second-last in preserving green space but first in attracting international students to our universities in 10 similar regions throughout the world.
JLL XQL

 
Streets paved with gold: Ipswich and its $12 million income-producing footpaths

2018-07-24 smh.com.au
Local Government Minister Stirling Hinchliffe’s predecessor in the Bligh Government was warned 10 years ago about “irregular” accounting by Ipswich City Council after the council revalued the city’s footpaths upwards by $12 million and claimed the amount as “income” in its annual financial statement.
XQL

 
'He asks us to front up $1bn': Indian billionaire under fire over Adani rail line

2018-07-19 theage.com.au
Adani's rail line to service its controversial Queensland mine should be in public hands and the Indian billionaire Gautam Adani should be paying for it, says former state under treasurer Sir Leo Hielscher.
XQL

 
'He asks us to front up $1bn': Indian billionaire under fire over Adani rail line

2018-07-19 smh.com.au
Adani's rail line to service its controversial Queensland mine should be in public hands and the Indian billionaire Gautam Adani should be paying for it, says former state under treasurer Sir Leo Hielscher.
XQL

 
'Bleeding cash': Ipswich Council's secretive development arm loses $80m

2018-06-27 abc.net.au
A strife-torn Queensland council has lost ratepayers more than $80 million through a secretive property development arm that could prove a costly timebomb, expert analysis obtained by the ABC reveals.
XQL

 
Big firms call for new SEQ city deal to deliver infrastructure boost

2018-06-06 smh.com.au
Queensland’s major construction and engineering companies have called on the state government to back a new city deal for south-east Queensland, as it did for Townsville in 2016, ahead of next Tuesday's budget.
XQL

 
Hospital parking stress in Brisbane's north to ease

2018-04-27 smh.com.au
Hospital parking stress in Brisbane’s north is set to ease with the state government to borrow money for a multi-storey car park.
XQL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...